Struggling with weight loss? FDA-approved Semaglutide and Tirzepatide help control appetite and support long-term results.
Patients who are having difficulty losing weight despite making significant changes in diet and increasing their exercise routines may turn to medical weight loss options such as Semaglutide or Tirzepatide. These are FDA-approved medications that offer effective treatment solutions when combined with healthy lifestyle changes.
Semaglutide is a GLP-1 receptor agonist and Tirzepatide targets GLP-1 and GIP receptors in the brain to regulate appetite, reduce cravings, and reprogram the brain on how and where to store fat in the body.
Both of these weight loss medications are taken on a weekly basis via injection to help patients lose the weight and keep it off for the long-term.
Semaglutide is classified as a glucagon-like peptide-1 (GLP-1) receptor agonist that is FDA approved to manage Type 2 diabetes and promote weight loss. The drug works to mimic the naturally-occurring GLP-1 hormone in your body by stimulating the production of insulin and restricting the release of glucagon to moderate blood sugar.
The result is a slower digestive process and a reduction in appetite, so you feel full longer, limiting your food intake, and helping you refrain from consuming the empty calories that only contribute to weight gain and negatively impact your overall health.
Semaglutide remains in the body for a much longer period of time than the naturally-occurring version of the GLP-1 hormone produced in your gastrointestinal tract. This allows for more successful weight loss and management results while keeping your glycemic levels in check.
Semaglutide is available by prescription, approved for weight loss by the FDA and proven safe and effective as a medical weight loss treatment option when prescribed by a licensed healthcare provider.
Some patients may notice marked changes in their weight, appetite, and A1C levels within the first three to four weeks of taking Semaglutide. Routine weight loss may start to occur within the first ten to twelve weeks.
Your results may vary based on a number of contributing factors, all of which can play a significant role in a patient’s ability to lose the weight and keep it off:
Semaglutide is intended for use by adults 18 years and older who have a body mass index of 27 kg/m2 or higher and have been diagnosed with one or more of these weight-related health conditions:
Adults with a body mass index of 30 kg/m2 or higher may take Semaglutide for weight loss without a diagnosis of any weight-related health conditions.
Patients who have been diagnosed with or have a medical history of the following health conditions should not take Semaglutide as a weight loss medication:
Patients typically start treatment with Semaglutide at low doses to give the body time to adjust to the effects of the medication which can decrease the risks of experiencing common side effects such as:
These side effects are often mild and go away in 48-72 hours in most cases.
Semaglutide has been shown to be the most effective when administered to patients who made healthy lifestyle choices such as eating a balanced, proper diet and getting plenty of routine exercise. These will help improve the chances of seeing the desired results when taking this medication and achieving optimal weight loss.
Tirzepatide is an FDA-approved weight loss medication that has been engineered to work by mimicking two different naturally-occurring hormones that are produced in the body and perform critical functions to regulate appetite, control food intake, and produce insulin to maintain healthy glycemic levels.
The GLP-1 (Glucagon-like peptide-1) and GIP (Gastric inhibitory polypeptide) hormones are formed in the intestine and each one is tasked with signalling the brain in different ways. The GLP-1 hormone suppresses appetite thus reducing the further consumption of any more food for the time being while the GIP hormone assists in triggering the brain to start the production of insulin while instructing it on where to store fat in the body and how much of it should be stored.
Tirzepatide works to perform the tasks of these hormones to help manage weight loss and maintain target weight once the goal has been achieved. The naturally-occurring variants of these hormones last for a limited time in the body once produced, Tirzepatide basically picks up where those hormones leave off, remaining in the body for much longer and providing the benefits for greater, longer-lasting results.
Patients have reported seeing significant changes after the very first dose, others may see results in the four to six weeks of taking the medication. Steady weight loss results become more apparent within the first couple of months and continue as long as the patient keeps taking the medication as directed.
Each patient is different so results may vary based on the following factors:
Adults aged 18 years or older with a body mass index of 25 kg/m2 or higher who have been diagnosed with one or more of the following weight-related health conditions is considered a good candidate for weight loss with Tirzepatide:
Adults who have a body mass index of 30 kg/m2 or higher without any diagnoses of weight-related health issues may also choose Tirzepatide as a safe and effective weight loss option.
Patients with a medical history of medullary thyroid carcinoma or a recent diagnosis of multiple endocrine neoplasia type 2 may not be able to take Tirzepatide for weight loss.
These side effects are typically mild and subside in just a couple of days.
Healthy lifestyle habits are always recommended but they become even more important for patients who have chosen Tirzepatide treatment to help them lose weight.
Good diet and routine exercise combined with a medical weight loss drug like Tirzepatide can help patients achieve their ideal weight goals faster and with greater success for long-term results.
Retatrutide is the next step in medical weight loss solutions that’s been developed as a treatment option for obesity and type 2 diabetes by acting as a triple agonist, targeting three key hormone receptors: GLP-1, GIP, and glucagon receptors. Similar to other medications like Semaglutide and Tirzepatide, this new option works by regulating appetite, managing your glucose metabolism, and moderating how your body stores fat and expends energy.
As of July 2025, Retatrutide remains in the clinical trial phase but, so far, has been shown to produce exceptional weight loss results. Patients who took Retatrutide during phase two trials of the drug at high dosing levels demonstrated a loss of more than 20% of their body weight and improved HbA1C levels.
That would make this new medication one of the most powerful and effective options on the market for accelerated weight loss and metabolic improvement.
Further data is pending as Retatrutide is currently undergoing late-stage phase three clinical trials to better determine the safety profile of the drug and investigate additional treatment functions stemming from its triple-action capabilities.
Yes, this medication has been linked to similar side effects as those commonly associated with other GLP-1 receptor agonist medications. These include:
These side effects have been shown to be mild to moderate and typically subside as dosing levels are gradually increased. These determinations are based on the most recent clinical trial data gleaned from phase three trial investigations.
Once you have explained your weight loss goals and the challenges you continue to face, we will work with you to develop a weight loss medication treatment regimen developed personally for you and the goals you wish to achieve. That will include an assessment of your weight, your age, your lifestyle habits, your health condition and medical history, all of which will play a role in deciding if you are a candidate for Semaglutide or Tirzepatide medical weight loss.
After your personalized treatment regimen has been developed, prescribed, and initiated, we will follow up with you every 1-2 months to assess your progress.
